Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety, tolerability, and immunogenicity study of VAX-31 in adults has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• VAX-31 (31-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-07-28